Indefinite Delivery Contract 75D30124D18655
Award Date
4/1/24
Last Date to Order
3/31/25
Federal Agency
CDC Pittsburgh
Awardee
Glaxosmithkline, LLC
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
This federal contract IDV award was issued by the Centers for Disease Control and Prevention (CDC) to procure pediatric vaccines for the Vaccines for Children (VFC) program. The 5-year, $1.35 billion multiple award contract aims to purchase standard commercial pediatric vaccines to support immunization efforts for eligible children, including those who are Medicaid-eligible, uninsured, American Indian/Alaska Native, or have insurance that does not cover vaccines. The prime contractor,...
This indefinite delivery contract, awarded by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC, provides for the purchase of 20 different pediatric vaccines for the CDC's Vaccines for Children program. The contract has a $986,824,450 ceiling value and a period of performance from April 1, 2020 through March 31, 2021. Glaxosmithkline, as the prime contractor, will supply vaccines such as DTaP, Hep A and B, Hib, HPV, MMR, pneumococcal, rotavirus, and varicella in...
The Centers for Disease Control and Prevention awarded multiple indefinite delivery contracts under the Vaccines for Children 2021 program to support pediatric immunization efforts. The contracts hold a potential value of $1.039 billion and were awarded to Glaxosmithkline, LLC for the period of April 1, 2021 through March 31, 2022. The contracts will provide 20 standard pediatric vaccines to the CDC's Immunization Awardees for distribution through the Vaccines for Children program and Section...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC, a pharmaceutical company, to provide up to 23 standard pediatric vaccines. The $1.14 billion, multiple-award contract has a period of performance from April 1, 2022 to March 31, 2023 and supports pediatric immunization programs under Section 317(j) of the Public Health Service Act and the Vaccines for Children program. The vaccines, which must have a minimum...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC, a pharmaceutical company, to provide a range of pediatric vaccines for the Vaccines for Children (VFC) program. The $1.26 billion, multiple-award IDC has a period of performance from April 1, 2023 through March 31, 2024. The contract aims to procure a minimum of 100 doses up to a maximum ranging from 100,000 to 13 million doses of 21 different pediatric vaccines,...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD) to Grifols USA LLC, a global healthcare company and manufacturer of essential plasma-derived medicines and vaccines. The contract, valued at a ceiling of $12,409,500, is for the supply of 20 standard pediatric vaccines to support immunization programs under the Vaccines for Children (VFC) program and Section 317(j) of the...
This indefinite delivery contract was awarded by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC as the prime contractor. The contract, valued at up to $1.25 billion, is part of the Vaccines for Children (VFC) 2015 program and provides for the delivery of various vaccines and pharmaceutical products to support federal immunization and disease prevention initiatives. Key products and services included under this multiple award IDV contract include seasonal influenza...
This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to Pfizer Inc., a large pharmaceutical manufacturer, to provide a range of standard pediatric vaccines to support immunization programs under the Vaccines for Children (VFC) program and Section 317(j) of the Public Health Service Act. The $1.6 billion multiple-award IDC has a period of performance from April 1, 2021 through March 31, 2022, with no small business set-asides utilized. The...
The federal contract IDV award is an Indefinite Delivery Contract held by Pfizer Inc. for the Centers for Disease Control and Prevention (CDC) Vaccines for Children (VFC) program. The contract has a ceiling value of $2,007,801,000.00 and a period of performance from April 1, 2025, through March 30, 2026. Under this IDV, Pfizer will provide a range of standard commercial pediatric vaccines to support immunization efforts for eligible children, including those who are Medicaid-eligible, uninsured,...
This federal contract IDV was awarded by the Centers for Disease Control and Prevention (CDC) to Sanofi Pasteur Inc. as the prime contractor. It is an indefinite delivery, indefinite quantity (IDIQ) contract with a ceiling value of $1,681,772,750 for the procurement of up to 23 standard pediatric vaccines over a 1-year period of performance from April 1, 2022 to March 31, 2023. The vaccines will support the CDC's Immunization Awardees and Vaccine for Children (VFC) program, which provides...